DDrare: Database of Drug Development for Rare Diseases

Searched query = "Cryopyrin-associated periodic syndrome", "Cryopyrin associated periodic fever syndrome", "Familial cold autoinflammatory syndrome", "FCAS", "Mucke-Wells syndrome", "MWS", "Chronic infantile neurologic cutaneous, and articular syndrome", "CINCA syndrome", "Neonatal onset multisystem inflammatory disease", "NOMID"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ACZ885; ACZ885 drug substance; ATI-450; Anakinra; Anti-interleukin-1B monoclonal antibody; C-028380; CANAKINUMAB; Canakinumab; Canakinumab (ACZ885); Canakinumab (WHO approval pending); Canakinumab (company code: ACZ885D); ILARIS; IZD174; IZD334; Ilaris; Inzomelid; Kineret; Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class; Recombinant human monoclonal antibody to human IL-1beta of the IgG1/K class; Rilonacept; Rilonacept 160 mg; Tranilast; XOMA 052

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01045772 (ClinicalTrials.gov)	January 2009	7/1/2010	Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)	A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany With Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome (CAPS), or Schnitzler Syndrome (SchS)	Muckle-Wells Syndrome;Schnitzler Syndrome	Drug: rilonacept	Charite University, Berlin, Germany	NULL	Completed	18 Years	N/A	Both	10	Phase 2	Germany
2	EUCTR2006-004290-97-DE (EUCTR)	19/12/2008	17/10/2006	A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS). - ACCILTRA1	A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS). - ACCILTRA1	The medical condition to be investigated was first described by Muckle and Wells 1962. The Muckle-Wells syndrome (MWS) is rare and characterized by chronic recurrent urticaria, periodic arthritis, sensorineural deafness, general signs of inflammation and secondary amyloidosis. Schnitzler syndrome (SchS) is rare and characterized by chronic, nonpruritic urticaria and a monoclonal immunoglobulin M gammopathy. Symptoms are recurrent fever, bone pain, muscle pain, arthralgia or arthritis.	Trade Name: Rilonacept	Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy	NULL	Not Recruiting			Female: yes Male: yes			Germany
3	NCT00288704 (ClinicalTrials.gov)	December 2005	6/2/2006	Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)	IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs	Familial Cold Autoinflammatory Syndrome (FCAS);Familial Cold Urticaria;Muckle-Wells Syndrome (MWS);Genetic Diseases, Inborn	Drug: rilonacept 160 mg;Drug: Placebo	Regeneron Pharmaceuticals	NULL	Completed	7 Years	N/A	All	104	Phase 3	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01045772
(ClinicalTrials.gov)

January 2009

7/1/2010

Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)

A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany With Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome (CAPS), or Schnitzler Syndrome (SchS)

Muckle-Wells Syndrome;Schnitzler Syndrome

Drug: rilonacept

Charite University, Berlin, Germany

NULL

Completed

18 Years

N/A

Both

Phase 2

Germany

EUCTR2006-004290-97-DE
(EUCTR)

19/12/2008

17/10/2006

A Single-Centre, Open Label Study of the Safety and Tolerability of Rilonacept in Subjects Living in Germany with Muckle-Wells Syndrome (MWS), a Cryopyrin-Associated Periodic Syndrome, or Schnitzler’s Syndrome (SchS). - ACCILTRA1

The medical condition to be investigated was first described by Muckle and Wells 1962. The Muckle-Wells syndrome (MWS) is rare and characterized by chronic recurrent urticaria, periodic arthritis, sensorineural deafness, general signs of inflammation and secondary amyloidosis. Schnitzler syndrome (SchS) is rare and characterized by chronic, nonpruritic urticaria and a monoclonal immunoglobulin M gammopathy. Symptoms are recurrent fever, bone pain, muscle pain, arthralgia or arthritis.

Trade Name: Rilonacept

Charité Universitätsmedizin Berlin, Department of Dermatology and Allergy

NULL

Not Recruiting

Female: yes
Male: yes

Germany

NCT00288704
(ClinicalTrials.gov)

December 2005

6/2/2006

Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)

IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs

Familial Cold Autoinflammatory Syndrome (FCAS);Familial Cold Urticaria;Muckle-Wells Syndrome (MWS);Genetic Diseases, Inborn

Drug: rilonacept 160 mg;Drug: Placebo

Regeneron Pharmaceuticals

NULL

Completed

7 Years

N/A

All

104

Phase 3

United States